Clinical research moves beyond compliance, focusing on smarter trial design, risk-based quality, and “evidence engineering” to deliver decisive, decision-ready results.
|Articles|January 30, 2012
Barley Beta-Glucan Approved for Canada
The approval means that Canadian food and beverage formulators can use the barley beta-glucan to up the fiber content of a variety of products.
Advertisement
Just months after receiving an EU article 14
Cargill says this soluble fiber is invisible when added to foods and beverages.
Advertisement
Related to this article
The company says the innovation, built on its CoreNhanced BioJourney platform, is designed for beverage and gummy formats.
AuraFen, BILVORA, and IMBE debut at SupplySide Global 2026, and the company will also highlight its CaFi digestive health ingredient.
Horphag Research's Sébastien Bornet breaks down the clinical science behind Robuvit, exploring how the caffeine-free French oak extract supports mitochondrial energy, mood stability, and stress resilience.
Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.
FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.
The company plans to present Organicaps capsules in size 0, 25 years of UC-II, and liquid-filled capsule technology.
DolCas Biotech is featuring the turmeric-derived ingredient Curcugen in Mānukora’s Mānuka honey and Numin’s cognitive-support drink.
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
CoreFX Launches CreaSHLD-IN Shielded Creatine at SupplySide Global 2026
2
Navigating Supplement Ingredients and Claims Regulations in Europe, the US, and Canada
3
Logical Square’s Portfolio Expands with Menopause, Prebiotic, and Extraction Introductions
4
FDA Finalizes NDI Guidance on Identity and Safety Information, Leaving Some Industry Concerns Open
5